Mutant KRAS decouples glycolysis from cell mechanics in non-small cell lung cancer

被引：0
|
作者：
Park, Jin Suk [1 ]
Sudderth, Jessica [1 ]
Gao, Boning [1 ]
Bachoo, Robert [1 ]
Danuser, Gaudenz [1 ]
机构：
[1] UT Southwestern Med Ctr, Dallas, TX USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.EPSO16-PR08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR08
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Current perspectives of KRAS in non-small cell lung cancer
    Harris, Ethan
    Thawani, Rajat
    CURRENT PROBLEMS IN CANCER, 2024, 51
  • [22] Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
    Tomasini, Pascale
    Walia, Preet
    Labbe, Catherine
    Jao, Kevin
    Leighl, Natasha B.
    ONCOLOGIST, 2016, 21 (12): : 1450 - 1460
  • [23] KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
    Adderley, Helen
    Blackhall, Fiona H.
    Lindsay, Colin R.
    EBIOMEDICINE, 2019, 41 : 711 - 716
  • [24] The role of EphA2 in the maintenance of cell viability of KRAS mutant non-small cell lung cancer.
    Amato, katherine R.
    Chen, Jin
    CANCER RESEARCH, 2013, 73 (08)
  • [25] De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer
    Singh, Anju
    Ruiz, Christian
    Bhalla, Kavita
    Haley, John A.
    Li, Qing Kay
    Acquaah-Mensah, George
    Montal, Emily
    Sudini, Kuladeep R.
    Skoulidis, Ferdinandos
    Wistuba, Ignacio I.
    Papadimitrakopoulou, Vassiliki
    Heymach, John V.
    Boros, Laszlo G.
    Gabrielson, Edward
    Carretero, Julian
    Wong, Kwok-Kin
    Haley, John D.
    Biswal, Shyam
    Girnun, Geoffrey D.
    FASEB JOURNAL, 2018, 32 (12): : 7018 - 7027
  • [26] Combined inhibition of MDM2 and MEK for KRAS mutant non-small cell lung cancer
    Hata, Aaron N.
    Archibald, Hannah L.
    Gomez-Caraballo, Maria D.
    DeBussche, Laurent R.
    Sidhu, Sukhvinder
    Watters, James
    Engelman, Jeffrey A.
    CANCER RESEARCH, 2014, 74 (19)
  • [27] A pooled shRNA screen for erlotinib sensitizers in Kras-mutant non-small cell lung cancer
    Cordes, Shaun
    Dompe, Nick
    Lee, James
    Li, Li
    Rivers, Celina
    Tang, Zhijun
    Luk, Wilman
    Bennett, Greg
    Shames, David
    Modrusan, Zora
    Davis, David P.
    CANCER RESEARCH, 2010, 70
  • [28] KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
    Rosell, Rafael
    Codony-Servat, Jordi
    Gonzalez, Jessica
    Santarpia, Mariacarmela
    Jain, Anisha
    Shivamallu, Chandan
    Wang, Yu
    Gimenez-Capitan, Ana
    Molina-Vila, Miguel A.
    Nilsson, Jonas
    Gonzalez-Cao, Maria
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 195
  • [29] Treatment of KRAS-Mutant Non-Small Cell Lung Cancer The End of the Beginning for Targeted Therapies
    Kaufman, Jacob
    Stinchcombe, Thomas E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (18): : 1835 - 1837
  • [30] Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
    Jeanson, Arnaud
    Tomasini, Pascale
    Souquet-Bressand, Maxime
    Brandone, Nicolas
    Boucekine, Mohamed
    Grangeon, Mathieu
    Chaleat, Solene
    Khobta, Natalyia
    Milia, Julie
    Mhanna, Laurent
    Greillier, Laurent
    Biemar, Julie
    Nanni, Isabelle
    Ouafik, L'houcine
    Garcia, Stephane
    Mazieres, Julien
    Barlesi, Fabrice
    Mascaux, Celine
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1095 - 1101
12345